Aliases & Classifications for Mood Disorder

MalaCards integrated aliases for Mood Disorder:

Name: Mood Disorder 12 15
Mood Disorders 55 43 44 73
Episodic Mood Disorder 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3324
MeSH 44 D019964
NCIt 50 C92200
SNOMED-CT 68 46206005 74421008

Summaries for Mood Disorder

MedlinePlus : 43 Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.

MalaCards based summary : Mood Disorder, also known as mood disorders, is related to delusional disorder and schizoaffective disorder, and has symptoms including alexithymia and psychiatric symptom. An important gene associated with Mood Disorder is DISC2 (Disrupted In Schizophrenia 2), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Norepinephrine and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves a disturbance in mood as the predominant underlying feature.

Wikipedia : 76 Mood disorder, also known as mood (affective) disorders, is a group of conditions where a disturbance in... more...

Related Diseases for Mood Disorder

Diseases related to Mood Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 delusional disorder 32.4 DRD2 DRD4 TH
2 schizoaffective disorder 32.2 BDNF COMT DISC1 DISC2 DRD2 HTR2A
3 postpartum depression 32.1 BDNF COMT CRH MAOA SLC6A4
4 asperger syndrome 32.1 BDNF DISC1 SLC6A4
5 dysthymic disorder 31.9 HTR2A MAOA SLC6A4
6 major depressive disorder 31.7 BDNF COMT CREB1 CRH DISC1 DISC2
7 endogenous depression 31.7 BDNF CRH HTR1A HTR2A MAOA NPY
8 atypical depressive disorder 31.6 CRH HTR2A MAOA SLC6A4
9 acth-secreting pituitary adenoma 31.6 CRH NR3C1 POMC
10 schizophrenia 2 31.5 DISC1 DISC2
11 schizophrenia 31.2 BDNF COMT DISC1 DISC2 DRD2 DRD4
12 bipolar disorder 30.9 BDNF COMT CREB1 CRH DISC1 DISC2
13 depression 30.7 BDNF CRH DISC2 HTR1A HTR2A MAOA
14 anxiety 30.7 BDNF COMT CRH HTR1A HTR2A MAOA
15 tardive dyskinesia 30.6 COMT DRD2 HTR2A
16 traumatic brain injury 30.5 BDNF COMT DRD2
17 brain injury 30.5 BDNF COMT DRD2
18 personality disorder 30.5 BDNF COMT DRD2 DRD4 HTR1A HTR1B
19 pathological gambling 30.3 DRD2 DRD4 HTR2A MAOA SLC6A4
20 social phobia 30.3 DRD2 HTR1A MAOA SLC6A4
21 bipolar i disorder 30.3 BDNF COMT HTR1A HTR2A SLC6A4
22 temporal lobe epilepsy 30.3 BDNF HTR1A NPY
23 alcohol abuse 30.3 BDNF DRD2 DRD4 HTR2A SLC6A4
24 substance abuse 30.2 BDNF COMT DRD2 DRD4 HTR1B MAOA
25 alexithymia 30.2 COMT DRD2 HTR1A SLC6A4
26 eating disorder 30.1 BDNF COMT CRH DRD2 NPY POMC
27 borderline personality disorder 30.1 BDNF COMT HTR1A HTR1B HTR2A MAOA
28 restless legs syndrome 30.1 DRD2 MAOA POMC TH
29 tobacco addiction 30.1 COMT DRD2 HTR2A MAOA SLC6A4 TPH1
30 fibromyalgia 30.1 COMT CRH HTR2A NPY SLC6A4
31 psychotic disorder 30.1 BDNF COMT DISC1 DRD2 DRD4 HTR1A
32 generalized anxiety disorder 30.1 BDNF COMT DRD2 HTR1A HTR2A MAOA
33 kleptomania 30.0 HTR1A MAOA SLC6A4
34 asthma 30.0 BDNF CREB1 CRH NPY NR3C1 POMC
35 schizophreniform disorder 30.0 COMT DRD2
36 autism 29.9 BDNF COMT DISC1 DRD2 DRD4 HTR1A
37 autism spectrum disorder 29.9 BDNF DISC2 HTR2A SLC6A4 TPH2
38 substance dependence 29.9 BDNF DRD2 DRD4 HTR1B MAOA POMC
39 irritable bowel syndrome 29.9 CRH SLC6A4 TPH1
40 obsessive-compulsive disorder 29.8 BDNF COMT CRH DRD2 DRD4 HTR1A
41 attention deficit-hyperactivity disorder 29.8 BDNF COMT DRD2 DRD4 HTR1A HTR1B
42 paranoid schizophrenia 29.8 BDNF COMT HTR2A MAOA SLC6A4 TPH2
43 oppositional defiant disorder 29.7 COMT DRD2 DRD4 MAOA SLC6A4 TPH2
44 panic disorder 29.7 BDNF COMT CRH HTR1A HTR2A MAOA
45 post-traumatic stress disorder 29.7 BDNF COMT CRH DRD2 HTR2A MAOA
46 alcohol dependence 29.5 BDNF COMT DRD2 DRD4 HTR1A HTR1B
47 mental depression 29.4 BDNF COMT CRH HTR1A HTR2A MAOA
48 organic mood syndrome 11.5
49 polycystic ovary syndrome 11.2
50 panic disorder 1 10.8

Comorbidity relations with Mood Disorder via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Anxiety
Deficiency Anemia Dysthymic Disorder
Heart Disease Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Mood Disorder:



Diseases related to Mood Disorder

Symptoms & Phenotypes for Mood Disorder

UMLS symptoms related to Mood Disorder:


alexithymia, psychiatric symptom

MGI Mouse Phenotypes related to Mood Disorder:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 BDNF COMT CREB1 CRH DISC1 DRD2
2 homeostasis/metabolism MP:0005376 10.34 BDNF COMT CREB1 CRH DISC1 DRD2
3 cardiovascular system MP:0005385 10.27 COMT CREB1 DRD2 HTR1A HTR1B MAOA
4 growth/size/body region MP:0005378 10.27 BDNF CREB1 CRH DISC1 DRD2 HTR1B
5 endocrine/exocrine gland MP:0005379 10.22 BDNF COMT CREB1 CRH DRD2 HTR1B
6 nervous system MP:0003631 10.22 BDNF COMT CREB1 CRH DISC1 DRD2
7 adipose tissue MP:0005375 10.13 CRH DRD2 HTR1B NPY NR3C1 POMC
8 integument MP:0010771 10.06 BDNF CRH DRD2 NR3C1 POMC SLC6A4
9 no phenotypic analysis MP:0003012 9.96 BDNF CRH DRD2 HTR1A HTR1B IMPA2
10 muscle MP:0005369 9.91 CREB1 DRD2 HTR1B HTR2A NR3C1 SLC6A4
11 normal MP:0002873 9.85 BDNF CREB1 CRH DRD2 IMPA2 NPY
12 renal/urinary system MP:0005367 9.5 COMT CRH DRD2 IMPA2 NPY NR3C1
13 respiratory system MP:0005388 9.28 BDNF COMT CREB1 CRH DRD2 NR3C1

Drugs & Therapeutics for Mood Disorder

Drugs for Mood Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 770)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
2
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
3
Trimipramine Approved Phase 4 739-71-9 5584 4055
4
Perphenazine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-39-9 4748
5
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 79617-96-2 68617
6
Nortriptyline Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 72-69-5 4543
7
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
8
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-48-6 2160
9
Fluvoxamine Approved, Investigational Phase 4,Phase 2,Not Applicable 54739-18-3 3404 5324346
10
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54910-89-3 3386
11
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 554-13-2
12
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
13
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 34841-39-9, 34911-55-2 444
14
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
15
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206
16
Cycloserine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-41-7 6234 401
17
Acetylcholine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-84-3 187
18
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Not Applicable 5949-44-0
19
Methyltestosterone Approved Phase 4,Phase 3,Not Applicable 58-18-4 6010
20
Testosterone Approved, Investigational Phase 4,Phase 3,Not Applicable 58-22-0 6013
21
Testosterone enanthate Approved Phase 4,Phase 3,Not Applicable 315-37-7 9416
22
Mianserin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 24219-97-4 4184
23
Mirtazapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 61337-67-5, 85650-52-8 4205
24
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6, 75614-87-8 774
25
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 5754
26
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-03-3
27
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84057-84-1 3878
28
Trazodone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 19794-93-5 5533
29
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
30
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
31
Vortioxetine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 508233-74-7 9966051
32
Ropinirole Approved, Investigational Phase 4,Not Applicable 91374-21-9, 91374-20-8 497540 5095
33
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
34
Norethindrone Approved Phase 4 68-22-4 6230
35
Polyestradiol phosphate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 28014-46-2
36
Copper Approved, Investigational Phase 4,Not Applicable 7440-50-8 27099
37
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757
38
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
39 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 979-32-8
40
Etomidate Approved Phase 4,Not Applicable 33125-97-2 667484 36339
41
Suvorexant Approved, Investigational Phase 4 1030377-33-3
42
Promethazine Approved, Investigational Phase 4,Phase 1,Not Applicable 60-87-7 4927
43
Diphenhydramine Approved, Investigational Phase 4,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
44
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
45
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
46
Eszopiclone Approved, Investigational Phase 4,Phase 3 138729-47-2 969472
47
Reboxetine Approved, Experimental Phase 4,Phase 2,Phase 1,Not Applicable 98769-81-4, 71620-89-8 123628 65856
48
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 132539-06-1 4585
49
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 106266-06-2 5073
50
Tranylcypromine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 155-09-9 441233

Interventional clinical trials:

(show top 50) (show all 4221)
# Name Status NCT ID Phase Drugs
1 Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene Unknown status NCT02237937 Phase 4 Paroxetine;Sertraline;Citalopram;Venlafaxine;Amitriptyline;Escitalopram;Amitriptylinoxide;Nortriptyline;Trimipramine
2 Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications Unknown status NCT01796132 Phase 4 SSRI/SNRI
3 DECARD: Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
4 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
6 Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
7 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
8 Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
9 Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
10 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
11 D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression Unknown status NCT02772211 Phase 4 Ketamine;D-cycloserine;Placebo
12 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
13 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
14 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
15 Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
16 Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
17 Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
18 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
19 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
20 Efficacy Study of Botox for Depression Unknown status NCT01556971 Phase 4 Botox;Saline Solution
21 Effect of Antidepressants on White Matter Structure Unknown status NCT01492621 Phase 4 Desvenlafaxine
22 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4 Duloxetine
23 Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression Unknown status NCT01390662 Phase 4
24 Depression Care Management for Depressed Elders in China Primary Care Unknown status NCT01287494 Phase 4 Sertraline
25 Lithium and Standard Therapy in Resistant Depression Unknown status NCT00927550 Phase 4 lithium;usual care
26 Duloxetine for Major Depression in Peri-/Postmenopausal Women Unknown status NCT00889369 Phase 4 Duloxetine
27 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
28 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
29 Medications for the Treatment of Dysthymic Disorder and Double Depression Unknown status NCT00234312 Phase 4 escitalopram and sertraline
30 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
31 Treatment of Mild and Subthreshold Depressive Disorders Unknown status NCT00226642 Phase 4 Sertralin;Placebo
32 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
33 Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression Unknown status NCT00106197 Phase 4 Bupropion
34 Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine Unknown status NCT02989727 Phase 4 Lamotrigine;Placebos
35 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) Unknown status NCT02051413 Phase 4 Venlafaxine extended release
36 Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
37 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
38 Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD) Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
39 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
40 Neurophysiologic Changes in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
41 Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
42 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
43 Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients Unknown status NCT02213016 Phase 4
44 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
45 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
46 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
47 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
48 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
49 Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales Unknown status NCT02210702 Phase 4 Ethinyl Estradiol 35mcg/Norethindrone 1mg;Ethinyl Estradiol 20mcg/Norethindrone 1mg
50 Efficacy Study of Escitalopram for Depression in Patients With Diabetes Unknown status NCT00650897 Phase 4 Escitalopram

Search NIH Clinical Center for Mood Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: mood disorders

Genetic Tests for Mood Disorder

Anatomical Context for Mood Disorder

MalaCards organs/tissues related to Mood Disorder:

41
Brain, Heart, Testes, Pituitary, Thyroid, Cortex, Ovary

Publications for Mood Disorder

Articles related to Mood Disorder:

(show top 50) (show all 1836)
# Title Authors Year
1
Developmental pathways towards mood disorders in adult life: Is there a role for sleep disturbances? ( 30243192 )
2019
2
Cortical biometals: Changed levels in suicide and with mood disorders. ( 30292148 )
2019
3
Cerebral oxidative metabolism mapping in four genetic mouse models of anxiety and mood disorders. ( 29885846 )
2019
4
Inflaming sex differences in mood disorders. ( 29955150 )
2019
5
Risk profiles of personality traits for suicidality among mood disorder patients and community controls. ( 29141103 )
2018
6
Decreased functional connectivity in the fronto-parietal network in children with mood disorders compared to children with dyslexia during rest: An fMRI study. ( 29845006 )
2018
7
A Review on the General Stability of Mood Disorder Diagnoses Along the Lifetime. ( 29607445 )
2018
8
Gut-Brain Axis and Mood Disorder. ( 29896129 )
2018
9
Food addiction, in obese patients seeking bariatric surgery, is associated with higher prevalence of current mood and anxiety disorders and past mood disorders. ( 29980127 )
2018
10
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
11
Epigenetics of Metabolic Syndrome as a Mood Disorder. ( 29707086 )
2018
12
The association between social skills deficits and family history of mood disorder in bipolar I disorder. ( 29590265 )
2018
13
BDNF signaling: Harnessing stress to battle mood disorder. ( 29592951 )
2018
14
Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety. ( 29543103 )
2018
15
Anxiety and Mood Disorder in Children With Autism Spectrum Disorder and ADHD. ( 29602900 )
2018
16
The association between low level of high-density lipoprotein cholesterol and mood disorder using time-dependent analysis. ( 28843914 )
2018
17
Impairment in delay discounting in schizophrenia and schizoaffective disorder but not primary mood disorders. ( 29808011 )
2018
18
Symptom Profile of Psychiatric Patients With Psychosis or Psychotic Mood Disorder in Prison. ( 29426253 )
2018
19
Using Neuroimaging to Develop Mood Disorder Diagnostic Biomarkers: A Good Forward Step and Some Considerations. ( 29735151 )
2018
20
Design of FRET Probes for SNP RS1006737, Related to Mood Disorder. ( 29541152 )
2018
21
Independent associations and effect modification between lifetime substance use and recent mood disorder diagnosis with household food insecurity. ( 29360862 )
2018
22
Inflammatory gene expression in adipose tissue according to diagnosis of anxiety and mood disorders in obese and non-obese subjects. ( 30504920 )
2018
23
NOP Ligands for the Treatment of Anxiety and Mood Disorders. ( 30535941 )
2018
24
Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions. ( 30417270 )
2018
25
Common environmental factors may underpin the comorbidity between generalized anxiety disorder and mood disorders via activated nitro-oxidative pathways. ( 30430941 )
2018
26
Differentiating borderline personality from bipolar disorder with the Mood Disorder Questionnaire (MDQ): A replication and extension of the International Mood Network (IMN) Nosology Project. ( 30502595 )
2018
27
Childhood maltreatment and adult medical morbidity in mood disorders: comparison of unipolar depression with bipolar disorder. ( 30232950 )
2018
28
Complexity analysis of spontaneous brain activity in mood disorders: A magnetoencephalography study of bipolar disorder and major depression. ( 29734005 )
2018
29
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. ( 29540132 )
2018
30
Mood disorder in the personal correspondence of Robert Burns: testing a novel interdisciplinary approach. ( 29992209 )
2018
31
Effects of stress on the auditory system: an approach to study a common origin for mood disorders and dementia. ( 30205652 )
2018
32
CAPON Is a Critical Protein in Synaptic Molecular Networks in the Prefrontal Cortex of Mood Disorder Patients and Contributes to Depression-Like Behavior in a Mouse Model. ( 30307500 )
2018
33
Does epilepsy increase the risk of needing to return to the hospital due to mood disorders? ( 30150276 )
2018
34
Increased risk of hospital admission for mood disorders following admission for epilepsy. ( 30068636 )
2018
35
Mood Disorders and Risk of Herpes Zoster in 2 Population-Based Case-Control Studies in Denmark and the United Kingdom. ( 29053820 )
2018
36
Psychosocial Difficulties in Adolescent Idiopathic Scoliosis: Body Image, Eating Behaviors, and Mood Disorders. ( 29803063 )
2018
37
Case-based care for pre-existing or new-onset mood disorders in patients undergoing infertility therapy. ( 29860578 )
2018
38
Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics. ( 29785336 )
2018
39
Translational new approaches for investigating mood disorders in rodents and what they may reveal about the underlying neurobiology of major depressive disorder. ( 29352034 )
2018
40
The experience and impact of stigma in Saudi people with a mood disorder. ( 30498517 )
2018
41
Genetic and environmental contributions to the association between mood disorder and periodontal disease: a cross-sectional study amongst female twins in the UK. ( 30537144 )
2018
42
A Case of Fronto-Temporal Dementia (FTD) Masquerading as Mood Disorder. ( 28452647 )
2018
43
Erratum to: Factors Associated with Mood Disorder Diagnosis Among a Population Based Cohort of Men and Women Living With and Without HIV in British Columbia Between 1998 and 2012. ( 28741132 )
2018
44
An epigenetic pathway approach to investigating associations between prenatal exposure to maternal mood disorder and newborn neurobehavior. ( 30068429 )
2018
45
Rare cause of manic period trigger in bipolar mood disorder: testosterone replacement. ( 30076163 )
2018
46
Complexity in mood disorder diagnosis: fMRI connectivity networks predicted medication-class of response in complex patients. ( 30084192 )
2018
47
Obstructive Sleep Apnea in Posttraumatic Stress Disorder Comorbid With Mood Disorder: Significantly Higher Incidence Than in Either Diagnosis Alone. ( 30107101 )
2018
48
Screening with the Korean Version of the Mood Disorder Questionnaire for Bipolar Disorders in Adolescents: Korean Validity and Reliability Study. ( 30121982 )
2018
49
Improving the Screening Instrument of Bipolar Spectrum Disorders: Weighted Korean Version of the Mood Disorder Questionnaire. ( 30121984 )
2018
50
Measuring the consequences of a bipolar or unipolar mood disorder and the immediate and ongoing impacts. ( 30145304 )
2018

Variations for Mood Disorder

Expression for Mood Disorder

Search GEO for disease gene expression data for Mood Disorder.

Pathways for Mood Disorder

Pathways related to Mood Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 CRH DRD2 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.92 COMT CREB1 DRD2 DRD4 MAOA TH
3
Show member pathways
12.91 BDNF CREB1 CRH DRD2 HTR2A POMC
4 12.46 COMT CREB1 HTR1A NPY POMC TH
5
Show member pathways
12.19 BDNF CREB1 DRD2 HTR1A HTR1B NPY
7
Show member pathways
11.92 BDNF CREB1 DRD2 MAOA TH
8
Show member pathways
11.89 DRD2 DRD4 HTR1A HTR1B HTR2A
9 11.86 HTR1A HTR1B HTR2A MAOA SLC6A4 TPH1
10
Show member pathways
11.81 DRD2 DRD4 TH
11 11.75 CREB1 CRH POMC
12 11.73 MAOA TH TPH1
13 11.68 CREB1 NR3C1 POMC
14
Show member pathways
11.65 COMT MAOA TH
15 11.53 BDNF CREB1 HTR1A HTR2A MAOA NR3C1
16
Show member pathways
11.41 MAOA SLC6A4 TH TPH2
17
Show member pathways
11.33 TH TPH1 TPH2
18
Show member pathways
11.16 TH TPH1 TPH2
19
Show member pathways
11.1 COMT MAOA SLC6A4
20
Show member pathways
11.01 COMT MAOA TH TPH1
21 10.95 HTR1A HTR1B HTR2A MAOA SLC6A4 TPH1
22 10.82 COMT MAOA TH
23
Show member pathways
10.79 COMT MAOA
24 10.76 BDNF CREB1
25 10.4 CRH POMC

GO Terms for Mood Disorder

Cellular components related to Mood Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.63 BDNF COMT CREB1 DRD2 HTR2A TH
2 integral component of postsynaptic membrane GO:0099055 9.5 DRD2 HTR2A SLC6A4
3 serotonergic synapse GO:0099154 9.26 HTR1B SLC6A4
4 integral component of presynaptic membrane GO:0099056 9.26 DRD2 HTR1B HTR2A SLC6A4
5 dendrite GO:0030425 9.23 BDNF COMT